Health effects models for nuclear power plant accident consequence analysis. Modification of models resulting from addition of effects of exposure to alpha-emitting radionuclides: Revision 1, Part 2, Scientific bases for health effects models, Addendum 2

Abstract

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.

Dose reduction and its influence on diagnostic accuracy and radiation risk in digital mammography: an observer performance study using an anthropomorphic breast phantom

“…It has been shown that the transferring of absolute risk values for breast cancer between populations is more stable than of relative risk values [31]. These estimates, however, were considered appropriate for a Swedish population, since similar [26][27][28][29] or identical [2,31] baseline rates have been used.…”

“…The number of deaths prevented as a result of mammography screening has earlier been assessed from the Malmö Mammographic Screening Trial (MMST) [25]. For the calculations of risk reduction of late effects, the following assumptions were made: two views are acquired per breast with an AGD of 1.3 mGy per view; screening involves an 80% participation rate; the loss of life expectancy occurs in the latter half of the remaining life; and there is a linear dose-response relationship and an age-related risk [6][7][26][27][28][29][30]. The risk reduction of late effects was calculated for 100 000 women undergoing annual screening from 40 to 49 years of age, i.e.…”

“…Number of prevented deaths MMST [25] 200 Number of fewer breast cancer fatalities due to a dose reduction by 50% Gilbert (NUREG/CR-4214) [26,27] 3.3 NRPB (NHSBSP) [28,29] 5.2 Holmberg [2,31] From the age at screening plus 10 years until: age 74, A 4.1 age 79, B 5.4 age 89, C 8.0 the rest of the women's lives, D 9.1 Fewer years lost in life expectancy due to a dose reduction by 50% Iinuma (ICRP) [7,30,32] 32…”